The Hunter Williams Podcast SGLT2 Inhibitors and GLP-1s | The Holy Grail of Longevity Medicine
16 snips
Nov 7, 2025 Explore the groundbreaking synergy between SGLT2 inhibitors and GLP-1 agonists that could redefine longevity medicine. Discover how these medications, initially designed for diabetes, offer unexpected benefits like improved cardiovascular health and kidney protection. Learn about the promising research linking SGLT2 use to reduced inflammation and potential longevity effects, along with insights on mouse studies and human outcomes. The conversation wraps up with practical tips on combining these therapies for optimal metabolic health.
AI Snips
Chapters
Books
Transcript
Episode notes
Personal Experience With Jardiance
- Hunter Williams started using Jardiance after reading literature and noticed steady improvements in longevity biomarkers.
- He paired it with microdoses of a GLP‑1 (Retatrutide) and observed additive benefits in his metrics.
Benefits Beyond Blood Sugar
- SGLT2 inhibitors were developed for diabetes but show major benefits beyond glucose control, like cardiovascular and renal protection.
- These off‑target effects make them promising candidates for geroprotective use in broader populations.
Mouse Lifespan Effects Are Sex Specific
- Canagliflozin extended median lifespan by ~14% in male mice but not females, showing sex‑specific and timing-dependent effects.
- Animal findings highlight complexity and the need for cautious translation to humans.
